Dose Evaluation of Head and Neck Cancer IMRT Treatment Planning Based on Gamma Index Analysis of Varian Halcyon 2.0 Linac

Varian Halcyon 2.0 linear accelerator was launched and became available for clinical use in 2018. Therefore, it is necessary to evaluate the accuracy of exit fluence quality assurance (QA) head neck cancer treatment planning, pretreatment, treatment. The twenty plannings has been evaluated by conducting gamma analysis QA pretreatment each field composite using criteria index 3 %/3 mm 2 %/2 mm. results are average value criterion fields on actual gantry angle null with passing rate (GPR) over 99 % (range 99.78 %-99.95 %) total treatments consisted 2717 fractions. GPR were 99.32 97.74 indexes mm, respectively. In addition, composites 95.46 81.38 Based this result, GPRs ≈ pixels. This means prediction dose accurate. nearly 90 %, showing that effective creating plans complex cases.